{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T14:31:53Z","timestamp":1714141913451},"reference-count":19,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":392,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,11,27]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>In our previous study, a triple therapy using tripotassium dicitrato bismuthate (TDB), josamycin and furazolidone achieved a suboptimal cure rate of <jats:italic>Helicobacter pylori<\/jats:italic> infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To investigate whether the addition of an antisecretory agent raises the cure rate using this regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>One hundred and twenty <jats:italic>H. pylori<\/jats:italic> positive patients with peptic ulcer disease or functional dyspepsia were randomly assigned to receive 1\u2010week quadruple therapy of TDB 240\u2003mg b.d., furazolidone 100\u2003mg b.d., josamycin 1000\u2003mg b.d. and famotidine 20\u2003mg b.d. (BFJF group), or triple therapy of TDB 240\u2003mg b.d., furazolidone 100\u2003mg b.d. and clarithromycin 250\u2003mg b.d. (BFC group). <jats:italic>H. pylori<\/jats:italic> status was assessed by histology and culture of gastric biopsy specimens before and at least 4\u2003weeks after completion of therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Seven patients (three in the BFJF group and four in the BFC group) dropped out. Eradication rates (intention\u2010to\u2010treat\/per protocol) were 90%\/95% in the BFJF group and 82%\/88% in the BFC group, respectively (<jats:italic>P<\/jats:italic>\u2003&gt;\u20030.05). Duodenal ulcer healing rates were 94% (16\/17) in the BFJF group and 80% (20\/25) in the BFC group, respectively (<jats:italic>P<\/jats:italic>\u2003&gt;\u20030.05). Mild side\u2010effects occurred in 11 (18%) patients in the BFJF group and 10 (17%) in the BFC group (<jats:italic>P<\/jats:italic>\u2003&gt;\u20030.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>One\u2010week quadruple therapy consisting of TDB, furazolidone, josamycin and famotidine achieves a high cure rate of <jats:italic>H. pylori<\/jats:italic> infection.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00845.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:40:11Z","timestamp":1047354011000},"page":"1519-1522","source":"Crossref","is-referenced-by-count":19,"title":["A new quadruple therapy for <i>Helicobacter pylori<\/i> using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine"],"prefix":"10.1111","volume":"14","author":[{"given":"Wen\u2010Zhong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu\u2010Dong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin\u2010Jin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido N. J.","family":"Tytgat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00487.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92962-2"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.4.477"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.1999.99307.x"},{"key":"e_1_2_6_6_2","first-page":"A36","article-title":"Bismuth, metronidazole and tetracycline + acid suppression in H. pylori eradication: a meta\u2010analysis","volume":"39","author":"Chiba N","year":"1996","journal-title":"Gut"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)22911-6"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00003.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199907000-00002"},{"key":"e_1_2_6_10_2","first-page":"A238","article-title":"Metronidazole resistance is high in Korea and Colombia and appears to be rapidly increasing in the US","volume":"110","author":"Reddy R","year":"1996","journal-title":"Gastroenterology"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00009.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0303.970320"},{"key":"e_1_2_6_13_2","first-page":"1203","article-title":"Clarithromycin, tetracycline, and bismuth: a new nonmetronidazole therapy for Helicobacter pylori infection","volume":"89","author":"Assi MT","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00172.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00492.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_C.39"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.42.2.166"},{"key":"e_1_2_6_18_2","first-page":"120","article-title":"Metronidazole quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study","volume":"45","author":"Graham DY","year":"1999","journal-title":"Gut"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00685.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00674.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00845.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00845.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00845.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T08:03:39Z","timestamp":1698566619000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00845.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11,27]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2000,11,27]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00845.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00845.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11,27]]}}}